Testing a new medication to slow lung changes in at-risk families

Plain-English translation of NCT07201922 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated August 2026 · How we translate trials

What is this trial?

This trial is testing a medication called to see if it can slow down early lung changes in people who have a family history of pulmonary fibrosis (a disease where lung tissue becomes scarred). You would take this medication twice daily for 2 to 3 years. Half of participants will receive the actual medication, and half will receive a placebo (a pill with no medicine), chosen randomly.

People with family members who have pulmonary fibrosis have a higher risk of developing lung scarring themselves. Researchers want to find a way to slow down or prevent early lung changes before they become serious, and this medication may help do that.

Do you qualify?

You likely qualify if…

you are at least 40 years old
you have at least one close family member (parent, sibling, or child) who has been diagnosed with pulmonary fibrosis or a related lung scarring condition
a lung scan shows early changes in your lungs called interstitial lung abnormalities
your lung function test results show your lungs are working at least 80% of normal capacity
you have not been diagnosed with advanced pulmonary fibrosis that requires current treatment

You likely don't qualify if…

you have already been diagnosed with pulmonary fibrosis that your doctor thinks needs treatment with approved medications
your lung function test results show a specific pattern suggesting advanced lung scarring
you have a connective tissue disease or other medical condition that causes lung scarring
you are currently taking or have previously taken nerandomilast, nintedanib, or pirfenidone

What participation looks like

You would take a tablet by mouth twice a day for about 2 to 3 years. You would visit the study site roughly every 3 months for the first 2 years, then every 6 months in the third year; during year 3 you would also have phone check-ins every 3 months. At these visits, doctors would perform lung function tests and chest scans to monitor how the medication is working and check for any side effects.

Testing a new medication to slow lung changes in at-risk families

What is this trial?

Do you qualify?

What participation looks like

Trial locations(55 sites)